Zydus receives final approval from the USFDA for Ivabradine Tablets
Ivabradine Tablets, 5 mg and 7.5 mg had annual sales of USD 136.5 mn in the United States
Ivabradine Tablets, 5 mg and 7.5 mg had annual sales of USD 136.5 mn in the United States
The company has received Form 483 with three observations
The product is expected to be launched in FY25
First-ever brain chemistry database will allow clinicians to quickly infer brain biomarker data to support the diagnostic process in conditions such as Alzheimer's Disease
Canagliflozin is a sodium-glucose co-transporter 2 (SGLT2) inhibitor
Bromfenac Ophthalmic Solution, 0.07% is indicated for the treatment of postoperative inflammation and reduction of ocular pain
The Product will be manufactured at the company's facility in Bengaluru
Dapagliflozin Tablets (RLD Farxiga) had estimated annual sales of USD 7282 million in the US
Subscribe To Our Newsletter & Stay Updated